PATENT CLAIM ANALYSIS

Application Number: 16063047
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "001000"]

Abstract:
The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

Claim (Index 1):
A prophylactic and/or therapeutic agent for choroidal neovascularization comprising: at least one agent selected from the group consisting of zaltoprofen, oxaprozin, tiaprofenic acid, flufenamic acid, mefenamic acid, sulindac, epalrestat, zafirlukast, amlexanox, seratrodast, and pharmaceutically acceptable salts thereof, as an active ingredient.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 94.0
- Lexical Diversity: 2.0
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12382702', '10685705', '13698518', '10773446', '14415994']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7416892631472554
- 35 USC 102 Novelty (BERT): 0.5274165596233327
- Combined Prediction Score: 0.7202619927948631
- Mean Citation Score: 307.786744
- Max Citation Score: 317.071
- Similarity Product: 213.40334710043672

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test